INVO Fertility, Inc. 8-K

What Happened
INVO Fertility, Inc. (NASDAQ: IVF) announced in an 8-K filed July 24, 2026 that it entered into an Any Market Purchase Agreement with Alumni Capital LP providing the company the right to sell up to $15.0 million of common stock (the Commitment Amount) — with a mutual option to increase the Commitment Amount up to $50.0 million. The company separately reported that its stockholders approved an amendment on July 23, 2026 to increase authorized common shares from 50,000,000 to 250,000,000 and re-elected all five director nominees and ratified its auditor.

Key Details

• Purchase facility: up to $15.0 million commitment (may be increased in writing up to $50.0 million). Term runs until the earlier of June 30, 2028, commitment exhaustion, delisting from an Eligible Market, or certain bankruptcy events.
• Pricing mechanics: company may direct sales at one of three purchase-price options: (1) 94% of the lowest 5-day VWAP; (2) 97% of the lowest prior-day traded price (1-day close); or (3) 85% of the lowest traded price for the prior five business days if the trading venue is not an Eligible Market. Closings occur within 1–5 business days depending on option chosen.
• Ownership and exchange caps: Nasdaq rule limits issuances to 19.99% of outstanding shares unless shareholder approval or a counsel opinion permits otherwise — stockholders approved issuance in excess of that cap on July 23, 2026. The Investor is contractually limited to beneficially owning no more than 9.99% (adjustable by mutual consent).
• Fees and conditions: INVO will pay a 1% commitment fee (cash or shares) and must file or confidentially submit an S-1 covering the shares by August 21, 2026 and use commercially reasonable efforts to obtain effectiveness within 120 days. The agreement contains customary reps, covenants and indemnities.

Why It Matters
This transaction provides INVO a flexible, on-demand equity financing tool to support expansion plans (including acquiring fertility clinics) and general corporate needs without an obligation to draw funds. For investors, the arrangement creates potential dilution because shares can be sold at a discount to recent market prices and the company now has substantially more authorized shares (250M) available for issuance. Shareholder approvals (including ability to issue above Nasdaq’s 19.99% cap and approval for potential future financings) reduce procedural barriers to using the facility, but any actual dilution will depend on if and when the company chooses to sell shares under the agreement.